Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Lymphoid 2Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 2Neoplasms 1Gastrointestinal Cancer Metastatic 1

Interventions

Prednisone 122Docetaxel 118enzalutamide 101pembrolizumab 96Sunitinib 86Leuprolide 84Abiraterone Acetate 83Nivolumab 78Gemcitabine 76bicalutamide 54Radiotherapy 54Goserelin 54Bevacizumab 54Cisplatin 52Magnetic Resonance Spectroscopy 49Everolimus 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 46Sorafenib 40Carboplatin 40Paclitaxel 37Radiosurgery 36atezolizumab 35abiraterone 33pazopanib 32cabozantinib 32Ipilimumab 32Axitinib 30Cyclophosphamide 29Androgen Antagonists 29Radiation 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Interferons × Genitourinary × Clear all
NCT01658813 2018-03-21

5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer

Western Regional Medical Center

Phase 2 Completed
18 enrolled 2 charts
GastrointestinalGenitourinaryThoracic

Gastrointestinal Cancer Metastatic

NCT00678288 2014-12-11

A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.

Bayer

Phase 2 Terminated
16 enrolled 6 charts
Genitourinary

Carcinoma, Renal Cell

NCT00117637 2014-10-31

BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

Bayer

Phase 2 Completed
189 enrolled 44 charts
Genitourinary

Carcinoma, Renal Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡